Related Experiment Video
Updated: Oct 30, 2025
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
The Phenomenon of Multidrug Resistance in Glioblastomas
Alexandr N Chernov1, Diana A Alaverdian2,3, Elvira S Galimova4
1Institute of Experimental Medicine, Russian Academy of Medical Sciences, Saint-Petersburg, Russia.
Abstract:
The most common and aggressive brain tumor in the adult population is glioblastoma (GBM). The lifespan of patients does not exceed 22 months. One of the reasons for the low effectiveness of GBM treatment is its radioresistance and chemoresistance. In the current review, we discuss the phenomenon of multidrug resistance of GBM in the context of the expression of ABC family transporter proteins and the mechanisms of proliferation, angiogenesis, and recurrence. We focused on the search of molecular targets among growth factors, receptors, signal transduction proteins, microRNAs, transcription factors, proto-oncogenes, tumor suppressor genes, and their single-nucleotide polymorphisms.
Insights
Glioblastoma (GBM) resistance to treatment stems from multidrug resistance mechanisms. This review explores GBM
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma (GBM) is the most frequent and aggressive adult brain tumor.
- Limited patient lifespan (median ~22 months) is linked to treatment resistance.
- Radioresistance and chemoresistance significantly hinder GBM treatment efficacy.
Purpose of the Study:
- To review the multidrug resistance (MDR) phenomenon in GBM.
- To explore the role of ABC transporter proteins in GBM MDR.
- To identify molecular targets for overcoming GBM resistance.
Main Methods:
- Literature review focusing on GBM multidrug resistance.
- Analysis of ABC transporter protein expression in GBM.
- Investigation of proliferation, angiogenesis, and recurrence mechanisms.
- Identification of potential molecular targets including growth factors, receptors, and genetic factors.
Main Results:
- Multidrug resistance is a key challenge in GBM treatment.
- ABC transporter proteins contribute to GBM's chemoresistance.
- Mechanisms of proliferation, angiogenesis, and recurrence are intertwined with resistance.
- Numerous molecular targets (e.g., growth factors, microRNAs, genetic polymorphisms) are implicated.
Conclusions:
- Understanding GBM's multidrug resistance is crucial for improving patient outcomes.
- Targeting ABC transporters and related molecular pathways may enhance GBM therapy.
- Further research into identified molecular targets is warranted for novel treatment strategies.
